Seventure Partners notes that CordenPharma has committed over 1B€ across three years.
Published
Signal category
Capital & Finance
Quote
“CordenPharma has committed over 1B€ across three years”
— Philippe Tramoy|Seventure Partners team
Company
Seventure Partners
We actively fund innovative companies within the two evolving fields of Digital technologies and Life sciences.
- Industry
- Venture Capital and Private Equity Principals
- Location
- Paris, FR
- Company size
- 44 employees
Seventure Partners is a long term equity investor that actively supports innovative companies aiming at generating positive impacts on Humankind, Society, Sustainability and the Planet. With €950m net commitments under management as of the end of 2022, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in 2 main areas: Life sciences (Biotech, Health & digital Health, Nutrition, Foodtech, Blue Economy, Aquaculture, Animal & Agriculture, Sport & Wellness …) with a specific interest for microbiome-related innovations across Europe, Israel, Asia and North America and Digital technologies (FinTech, RetailTech etc…) in Western Europe. Investments can range between €500k and €10m per round and up to €20m per company, from early to late stage, growth, pre-IPO and IPO. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com
Founded 1997